Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPACT-MI trial of empagliflozin after acute myocardial infarction
NL-OMON56313Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Empagliflozin plus standard of care with Placebo plus standard of care (2 arms). Started Jul 2021; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON56313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56313.